Skip to content

Effect of Dairy Consumption on Glycemic Control, Body Weight and Cardiovascular Risk Factors

The Effect of Dairy Product Consumption on Glycemic Control, Body Weight and Cardiovascular Risk Factors in Patients Enrolled in the Joslin Weight Achievement and Intensive Treatment (Why WAIT) Program: A Prospective Cohort Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02896140
Enrollment
51
Registered
2016-09-12
Start date
2016-04-01
Completion date
2018-09-01
Last updated
2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 2, Obesity

Keywords

Type 2 diabetes, Obesity, Nutrition, Dairy

Brief summary

The aim of this study is to determine the relationship between the percentage of calories from dairy intake and long-term glycemic control and weight maintenance in patients with type 2 diabetes who participate in an intensive lifestyle intervention program. The investigators hypothesize that overweight and obese patients with type 2 diabetes who consume higher percentage of calories from dairy products during intensive lifestyle intervention programs have better glycemic control and maintenance of weight loss as compared to those who consume lower percentage of calories from dairy products.

Detailed description

This is a prospective, observational clinical study where the daily intake of dairy products will be recorded and analyzed in 50 overweight/obese subjects with type 2 diabetes enrolled in the Weight Achievement and Intensive Treatment (Why WAIT) program. The Weight Achievement and Intensive Treatment (Why WAIT) program is a 12-week multidisciplinary program developed by Joslin Diabetes Center for intensive diabetes weight management in clinical practice. It includes the following components that are provided in a group setting: (1) intensive medical treatment provided by an endocrinologist and a registered nurse; (2) a structured dietary plan provided by a registered dietitian; (3) an individualized exercise training program provided by an exercise physiologist; (4) cognitive behavioral modification provided by a behavioral therapist. Participants will be enrolled in this study for a period of 24 weeks. They will attend the Weight Achievement and Intensive Treatment (Why WAIT) program during the first 12 weeks of the study and will be followed for another 12 weeks after the program (the maintenance phase). During the intervention phase, participants will receive group education on a weekly basis for 12 consecutive weeks. During maintenance phase, participants will receive a monthly, 15 minute long, follow up phone call from the study dietitian. Participants will be instructed to complete a 3-day food log before each visit. They will also be asked to record their dairy intake on a daily basis in a dedicated log book. These logs will be collected and analyzed by the study dietitian. Dairy consumption will be calculated as the sum of servings per day of milk, cheese, yogurt, and other dairy foods.

Interventions

OTHERType 2 diabetes in WhyWAIT Program

The sum of servings per day of milk, cheese, yogurt, and other dairy foods.

Sponsors

Joslin Diabetes Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Subject is participating in the Weight Achievement and Intensive Treatment (Why WAIT) program 2. Subject is male or female ages 18-75 3. Subject has type 2 diabetes for at least three months prior to screening and treated with any antihyperglycemic medication

Exclusion criteria

1. Subject is pregnant or lactating 2. Subject has a heart pacemaker

Design outcomes

Primary

MeasureTime frame
Change in Hemoglobin A1C (A1C)24 weeks

Secondary

MeasureTime frame
Change in body weight24 weeks
Change in low-density lipoprotein (LDL)24 weeks
Change in high-density lipoprotein (HDL)24 weeks
Change in total cholesterol24 weeks
Change in triglycerides24 weeks
Change in fasting plasma glucose24 weeks
Change in Homeostatic model assessment (HOMA) insulin resistance (IR) index24 weeks
Height in meters24 weeks
Change in body fat percentage24 weeks
Change in fat free mass24 weeks
Change in total body water24 weeks
Change in waist circumference24 weeks
Change in trunk fat percentage24 weeks
Change in visceral fat level24 weeks
Change in blood pressure24 weeks
Change in c-reactive protein level24 weeks

Countries

United States

Contacts

PRINCIPAL_INVESTIGATOROsama Hamdy, MD, PhD

Joslin Diabetes Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 11, 2026